Substance Use and HIV Action for Reentry and Engagement.
Part of paid clinical trials in Atlanta, Georgia.
- Sponsor
- Emory University
- Study ID
- NCT06810973
- Status
- Enrolling By Invitation
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SUCCESS-E — BEHAVIORALSUCCESS-E is a previously developed intervention based on the evidence-based Antiretroviral Treatment and Access to Services (ARTAS) intervention, modified for those detained within a jail system. It is a manualized six-session program delivered by a case management team, composed of a professional case manager and paraprofessional peer navigators. In Jail Sessions: 1. Build Trust 2. Assess Strengths 3. Explore life on ART Post-Release Sessions: 4. Link with care 5. Enhance self-efficacy for HIV care/PrEP 6. Future transitions
- Enhanced Standard of Care — BEHAVIORALA list of referral sites for follow-up SUD care will be shared. This information sharing without strength-based, longitudinal case management will be an enhancement to treatment as usual. Also, information about HIV/PrEP follow-up in the community will be placed around the jail, such as affixed to the nurses' medication carts that they push from housing unit to unit, twice a day when residents are due for prescription medications.
- Key Informant Interviews — BEHAVIORALKey informant interviews (KII) will be conducted with jail staff and community stakeholders in the R61 phase to examine perceptions, barriers, and facilitators to SUD and HIV/PrEP service and treatment utilization, as well as document the experiences of SUCCESS-E participants from the pilot phase.
Study Details
This study will test a behavioral intervention with a case manager/peer navigator team pairing with clients to deliver transition planning services. The interactions help clients recognize and use their strengths. The goal is to see if this approach improves clients' ability to access healthcare and drug treatment after being released from jail.
Key Dates
- Start date
- Jun 9, 2025
- Status verified
- Aug 2025
- Primary completion
- Aug 31, 2026
- Completion
- Aug 31, 2026
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: SUCCESS-EParticipants with SUD, living with HIV or at high risk for seroconversion, will be placed in strength-based case management, delivered by a case manager and peer navigators, both in jail and in the community, leading to linkage and retention in healthcare and SUD treatment.
- Other: Control GroupParticipants not placed in the intervention group will have healthcare services inform them of possible medical homes for HIV/PrEP care and a list of referral sites for follow-up SUD care.
- Other: Key informant interviews (KII)Jail staff and community members willing to participate in Key Informant Interviews (KIIs)
Primary Outcome Measure
Linkage to ART [ Time Frame: 3 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Fulton County Jail | Atlanta | Georgia | 30318 | - |
Find similar trials in Atlanta, GA
By condition
By specialty
By research site
Related Studies
- Inflammation and Depression in People With HIVPHASE2 · Recruiting · Emory University · Atlanta, Georgia
- Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIVPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama
- Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good HealthPHASE1 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California
- A Study of VRC07-523LS, PGT121.414.LS, and PGDM1400LS Broadly Neutralizing Monoclonal Antibodies Given Intravenously in Adult Participants Without HIVPHASE2 · Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Birmingham, Alabama